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Background: Early recognition of antiretroviral therapy (ART) failure in resource limited settings is a challenge given
the limited laboratory facilities and trained personnel. This study aimed at describing the incidence, risk factors and
the resistance associated mutations (RAMs) of first line treatment failure among HIV-1-infected children attending
the Joint Clinical Research Centre (JCRC), Kampala, Uganda.
Methods: A retrospective cohort of 701 children who had been initiated on ART between January 2004 and
September 2009 at the JCRC was studied. Data of children aged 6 months up to 18 years who had been started on
ART for at least 6 months was extracted from the clinic charts. The children who failed the first-line ART were taken
as cases and those who did not fail as the controls. Data was analysed using STATA version10.
Results: Of 701 children, 240(34%) failed on first line ART (cases) and 461(66%) did not fail (controls). The overall
median time (IQR) to first line ART failure was 26.4 (18.9 – 39.1) months. The factors associated with treatment
failure were poor adherence [(OR = 10, 95 CI: 6.4 – 16.7) p < 0.001], exposure to single dose nevirapine (sdNVP)
[(OR = 4.2, 95% CI:1.8-9.4), p = 0.005] and a NVP containing regimen [(OR = 2.2,95% CI:1.4-3.6), p < 0.001]. Of 109
genotypic resistance profiles analyzed, the commonest non nucleoside reverse transcriptase inhibitor (NNRTI) resistance
associated mutations (RAM) were: K103N (59; 54%)), Y181C (36; 27%)) and G190A (26; 24%)) while the commonest
nucleoside reverse transcriptase inhibitor (NRTI) RAM was the M184V (89; 81%). Thymidine analogue- mutations
(TAMs) were detected in 20% of patients.
Conclusions: One in three children on first-line ART are likely to develop virological treatment failure after the first
24 months of therapy. Poor adherence to ART, a NVP based first-line regimen, prior exposure to sdNVP were
associated with treatment failure.Introduction
Antiretroviral therapy (ART) has been shown to reduce
human immunodeficiency virus (HIV) associated mor-
bidity and mortality by restoring and preserving the
immunological function [1-6]. Globally, there has been a
pronounced increase in scaling up ART services notably
in sub-Saharan Africa [7,8], with Uganda being among the
pioneering countries [9]. However, ART is long term treat-
ment with the potential of drug toxicity and probable
emergency of resistance which results into treatment
failure. Treatment failure is suboptimal response or a lack* Correspondence: robertsebunya3@gmail.com
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reproduction in any medium, provided the orof sustained response to therapy using either clinical,
immunological and virological criteria [10]. Paediatric
antiretroviral therapy cohorts in low income countries have
reported that response to ART is as good or comparable to
that in high income countries [4,11]. Single dose nevirapine
(sNVP) has been widely used for prevention of mother
to child transmission (PMTC) in low resource settings
and NVP continues to be used as part of the backbone of
non-nucleoside reverse transcriptase inhibitors (NNRTI)
among HIV infected children [12]. Some of these cohorts
have reported occurrence of resistant mutations to sNVP
with subsequent treatment failure [13,14]. The incidence
and risk factor for first line ART has not been described
in Uganda. In this study we describe the incidence, risk
factors for the first line treatment failure among childrenl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Uganda. We also describe the resistance associated
mutations in this cohort.
Whereas viral load is the ideal tool for monitoring ART
response, clinical and immunological monitoring are widely
used in resource limited settings like Uganda. There is
sufficient evidence suggesting a poor correlation between
clinical/immunological and virological ART failure [15-17].
In Uganda like many other sub-Saharan countries there is
paucity of data regarding paediatric virological treatment
failure.
Methods
This was a retrospective cohort (1-5 yr) follow up. We
studied children who started ART at the Joint Clinical
Research Centre (JCRC), Kampala, Uganda under the
Timetable for Regional Expansion of antiretroviral Therapy
(TREAT) program between 2004 – 2009 since all children
had similar free scheduled laboratory monitoring within
this period.
Children who were aged 6 months to 18 years and had
been initiated on ART for at least 6 months were included
in the study. Those who had confirmed first line ART
treatment failure and referred for second line ART were
excluded plus those charts of children which had key
missing information like treatment history and laboratory
results (CD4 counts, viral load) were excluded.
Study setting
The study was conducted at the JCRC Kampala, Lubowa
campus, which houses the headquarters of this HIV care
and research institution. It is located 10 km off Entebbe
road from Kampala, the capital city of Uganda. At the
time of this study, the centre cared for over 2000 HIV
infected children majority of whom were perinatally
infected and over 10,000 adults with respective outpatient
clinics opening from Monday to Friday, 8.00a.m to 5p.m,
excluding public holidays. The centre provided free
services such as ART, opportunistic infections prophylactic
medication, adherence counseling, routine laboratory
monitoring tests, and nutritional supplementations. Among
the routine laboratory monitoring tests performed were
CD4 cell counts and CD4 percentages every 6 months,
liver and renal function tests, plasma HIV-1(RNA) viral
loads, and genotypic resistance testing when treatment
failure was confirmed.
The pediatric clinic had over 1500 children under care
with approximately 37 staff members namely; six pediatri-
cians, nine nurses, four counsellors, two home visitors, one
pharmacist, two pharmacy technicians, two record officers
and one data assistant. Others included play room supervi-
sors (2), phlebotomists (2) and support staff(3) with exclu-
sion of the inpatient/ward staffs. At this clinic, treatment
seeking children are recruited into care following selfreferral by caretakers and referral from other health
centres. All HIV exposed infants awaiting DNA PCR
results and those infected were/are initiated on Co- tri-
moxazole prophylaxis. Since most children at the clinic
have/had resource constraints, most were, recruited under
the PEPFAR funded programs Timetable for Regional
Expansion of Anti-retroviral Therapy (TREAT).
The criteria for ART initiation and switching, as well as
the ART regimens were by the WHO guidelines for ART
initiation in infants and children [18]. Most children above
1 year received medication in tablet formulation with doses
determined using WHO weight bands (WHO 2004,2006)
[18,19]. Infants received medication largely largely in syrup
form determined per kilogram body weight.
Cohort description
We reviewed the clinic charts of patients who had been
initiated on ART between Jan 2004 to September 2009, as
identified from the patient care database at JCRC. This was
the period of the TREAT program where all the children
had similar scheduled laboratory monitoring tests like the
viral loads, resistance testing and CD4 counts. The baseline
was taken to be the time children were initiated on ART.
The ART regimen consisted of 2 nucleoside reverse
transcription inhibitors (NRTIs; lamivudine, zidovudine,
stavudine and abacavir) and a non-nucleoside reverse tran-
scription inhibitor (NNRTI, either nevirapine or efavirenz).
Infants (children less than 1 year) were given syrups and
older children were given tablets. The children below 3 years
of age who developed Tuberculosis were put on triple NRTI
regimens, to avoid the drug-drug interaction between
nevirapine and rifampicin. The dosage depended on the
child’s weight. In case of virologic failure, the NNRTI
could be switched to the boosted protease inhibitor
(PI) lopinavir/ritonavir with 2–3 NRTIs as a second-
line regimen. Most of the secondline ART was chosen
depending on the resistance profiles that had been
done in most of the children who had failed firstline.
The commonest second line ART used was combivir
(lamivudine/zidovudine)didanosine(ddl) and alluvia.
In this cohort Information regarding Pre-exposure to
single dose nevirapine or other antiretroviral drugs as part
of a prevention of mother-to- child transmission (PMTCT)
could not be entirely ascertained, because some children
were orphans and brought in by distant relatives and hence
the required information was not readily available.
Laboratory assessment at the study site
Laboratory measurements included a complete blood cell
count, CD4 lymphocyte count, and quantitative measure-
ment of HIV load. Quality control assurance was done
in reference to international accredited laboratories; UK
National External Quality Assessment Service (UKNEQAS)
and College of American Pathologists (CAP). Viral load
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assay, version 1.5 (Roche Molecular Systems),with a mini-
mum detection limit of 400 copies/ml. CD4 lymphocytes
were analyzed by flow cytometry (Bendict Dickson, USA).
Genotypic resistance sequencing was done using in house
primers. The sequences were edited using BioEdit Sequence
Alignment Editor (Version 7.0.5) and analyzed using the
HIV drug resistance database of Stanford University [20]
for children who had a viral load greater than 2000 copies
since this was the threshold beyond which mutations could
be detected in the laboratory. The CD4 count and viral load
were periodically done every 6 months during the routine
visit to the out-patient clinic.
Data collection
We extracted the children’s demographic and ART treat-
ment information from their medical records at the clinic
using a pre tested standardized data extraction form. This
information included their gender, age at the time of
assessment and ART initiation, WHO clinical staging
at the start of ART, CD4 count/percentage and follow
up viral loads at the time of switch were abstracted.
Data regarding the use of sdNVP in PMTCT, first-line
ARTand the serial Weight for Height plus the six monthly
follow up tests for up to five years till virological failure
was first detected were extracted. History of opportunist
infections, resistance mutation tests that were done before
switching to second line ART tests were also recorded
using the same tool. Adherence to ART was the docu-
mented adherence level by the then attending clinician
during the fellow up visits. It was done by pill counts and
self reports especially in the older children. An adherence
greater than 95% was considered as good adherence while
that less than 95% was taken as poor adherence.
Virological failure was defined as inability to achieve or
maintain suppression of HIV replication to non detectable
range. For this study we used virological failure as the
determinant of treatment failure.
Statistical analysis
The cumulative incidence of first-line ART failure was
ascertained from the proportion of children with viral
load > 2000 copies per ml at any time during follow up.
Kaplan Meier survival curves plus Cox regression were
used to estimate the median time to first line ART treat-
ment failure which was the primary outcome. The Wald
test was used to compare the incidence rates of ART failure
in the different ART first line regimens. Factors associated
with treatment failure were ascertained by comparing
various variables among children who failed (cases) with
those who never failed (controls) using the chi-square
test for categorical data and student t test for continuous
variables. Logistic regression was done to determine the
factors that independently predict ART treatment failure.All social demographic and clinical characteristics (vari-
ables) were subjected to univariate analysis as (shown in
Table 1 and 2). And factors whose p-valve was less than
0.02 at univariate analysis were included in multivari-
ate analysis. The model was then built by dropping the
most insignificant factor one at a time with factors
whose P-valve was (<)0.05 were taken to be the factors
that were independently associated with treatment failure
(Table 3).
All analyses were done using STATA version 10 (Reference:
StataCorp LP, 4905 Lakeway Drive, College Station,
Texas 77845, USA).
Ethical consideration
Ethical clearance was obtained from the School of Medicine
Research and Ethics committee (SOMREC), Makerere
University College of Health Sciences. Waiver of consent
was sought from the SOMREC and JCRC Institutional
Review Board (IRB) Research and Ethics Committee (REC).
Permission to carry out the study was also obtained from
JCRC and the Uganda National Council of Science and
Technology (UNCST).
Results
We queried 1068 patients’ records from the data base who
had been initiated on ART between January 1st 2004 and
September 30th 2009, at the JCRC paediatric out-patient
clinic. Three hundred and sixty seven (367) records were
excluded because some had key missing data including
CD4 counts, viral loads, weight, height, resistance muta-
tions profile results, and information on first line ART, or
had been referred from other centres after documented
failure on first line and others lacked baseline characteris-
tics. The remaining 701 children’s records were included
as shown in (Figure 1). Pre-exposure to single dose nevira-
pine or other antiretroviral drugs as part of a prevention
of mother-to- child transmission (PMTCT) regimen could
not be entirely ascertained in all the children though,
because some children were orphan and brought in by
distant relatives and hence the required information was
not readily available. However 31 children had exposure
to sdNVP and of those 29 were also started on neviraipne
containing firstline regimen. The median baseline CD4
counts absolute and percentage at start of ART for those
who failed and never failed were 241 and 313 cells,15%
and 16% respectively.. Most of the children were in clinical
stage two of the WHO paediatric HIV staging and were
above 5 years of age. Pulmonary tuberculosis being the
commonest opportunistic infection as shown in Table 4.
Incidence of first line virological treatment failure
Among 701 participants, 240 (34%) cumulatively failed
first-line ART. The median time to failure in months was
26.4 IQR (18.9 – 39.1). 140 (58.3%) failed in 24+ months,
Table 1 A comparison of the social demographic and clinical characteristics between the cases and the controls at ART
initiation of ART
Characteristic Cases (n = 240) Controls (n = 461) RR (95 % CI) P- value
Age <=5 years 91 (37.9) 174 (37.7) 1.00 (0.81 – 1.24) 0.9643
>5-10 years 61 (25.4) 139 (30.2) 0.85 (0.67 – 1.09) 0.1877
>10 – 18 years 88 (36.7) 148 (32.1) 1.14 (0.92 – 1.41) 0.2252
Gender Female 109 (45.4) 221 (47.9) 0.93 (0.76 – 1.15) 0.5255
Male 131 (54.6) 240 (52.1) 1.07 (0.87 – 1.31) 0.5255
Next of kin Parents 162 (67.5) 302 (65.5) 1.06 (0.85 – 1.32) 0.5971
Grandmother 25 (10.4) 81 (17.6) 0.65 (0.46 – 0.93) 0.0121*
Other 53 (22.1) 78 (16.9) 1.23 (0.97 – 1.57) 0.0961
Care taker education level None 63 (26.5) 101 (22.3) 1.15 (0.92 – 1.45) 0.2262
Primary 76 (31.9) 175 (38.7) 0.82 (0.66 – 1.03) 0.0783
Secondary 58 (24.4) 102 (22.6) 1.07 (0.84 – 1.35) 0.5937
Tertiary (not university) 26 (10.9) 43 (9.5) 1.10 (0.80 – 1.52) 0.5570
University 15 (6.3) 31 (6.9) 0.94 (0.61 – 1.45) 0.7808
Distance from JCRC ≤10 km 104 (44.3) 157 (35.4) 1.27 (1.03 – 1.56) 0.0248*
11 – 20 km 91 (38.7) 194 (43.8) 0.87 (0.70 – 1.08) 0.2032
>20 km 40 (17.0) 92 (20.8) 0.85 (0.64 – 1.12) 0.2411
Past hospitalization Yes 105 (43.8) 198 (43.2) 1.01 (0.82 – 1.25) 0.8955
No 135 (56.2) 260 (56.8) 0.99 (0.80 – 1.21) 0.8955
Episodes of No hospitalization 2 (2.0) 3 (1.5) 1.16 (0.39 – 3.44) >0.999†
hospitalization 1-2 times 68 (66.6) 120 (61.9) 1.15 (0.82 – 1.61) 0.4139
≥ 3 times 32 (31.4) 71 (36.6) 0.86 (0.61 – 1.21) 0.3697
Opportunistic infections TB 51 (21.3) 90 (19.5) 1.07 (0.84 – 1.37) 0.5883
Oral Candidiasis 39 (16.3) 64 (13.9) 1.13 (0.86 – 1.48) 0.4009
Cryptococcal meningitis 3 (1.3) 2 (0.4) 1.76 (0.85 – 3.63) 0.3448†
Kaposi sarcoma 2 (0.8) 5 (1.1) 0.83 (0.26 – 2.70) >0.999†
Pneumocystic pneumonia 3 (1.3) 5 (1.1) 1.01 (0.44 – 2.70) >0.999†
Oesophageal candiasis 1 (0.4) 9 (2.0) 0.29 (0.04 – 1.86) 0.1770†
Chronic diarrhoea 4 (1.7) 18 (3.9) 0.52 (0.21 – 1.28) 0.1165†
Bacterialmeningitis 2 (0.8) 5 (1.1) 0.83 (0.26 – 2.70) >0.999†
HAART Regimen EFV 113(49.3) 278 (64.5) 0.67 (0.54 – 0.82) 0.0002*
NVP 116 (50.7) 153 (35.5) 1.49 (1.21 – 1.84) 0.0002*
Prior exposure to sdNVP Yes 33 (13.8) 45 (9.9) 1.26 (0.95 – 1.67) 0.1253
No 207 (86.2) 410 (90.1) 0.79 (0.60 – 1.05) 0.1253
Adherence Poor 116 (48.3) 56 (12.2) 2.88 (2.39 – 3.46) <0.0001*
Good 124 (51.7) 405 (87.8) 0.35 (0.29 – 0.42) <0.0001*
I 37 (15.4) 65 (14.1) 1.07 (0.81 – 1.42) 0.6389
WHO Stage II 106 (44.2) 198 (42.9) 1.03 (0.84 – 1.27) 0.7578
III 85 (35.4) 163 (35.4) 1.00 (0.81 – 1.24) 0.9877
IV 12 (5.0) 35 (7.6) 0.73 (0.44 – 1.21) 0.1929
CI = Confidence interval, * Significant effect, †Fisher’s exact test.
Sebunya et al. AIDS Research and Therapy 2013, 10:25 Page 4 of 10
http://www.aidsrestherapy.com/content/10/1/2580 (33.3%) failed within 12–24 months, 11(4.6%) failed
within 6–12 months and only 9(3.8%) in within the first
6 months. This is also illustrated in Figure 2.The factor that was independently associated with time
to virologcal failure was poor adherence to ART as shown
in Table 5 below.
Table 2 Baseline CD4 counts and viral loads of study participants at ART initiation of the 701 children on ART
Cases Controls
Median (IQR) Median (IQR) P value*
Absolute CD4 count Overall 241 (79–534) 313 (127–625) 0.035
≤ 5 years 542 (273 – 1214) 728 (461 – 1129) 0.038
>5-10 years 257 (133–474) 272 (147–382) 0.873
>10 – 18 years 135 (50–210) 130 (44–262) 0.622
Mean (SD) Mean (SD) P value
Percentage CD4 count Overall 15 (10.5) 16 (11.0) 0.223
≤ 5 years 19 (10.9) 19 (9.5) 0.945
>5-10 years 15 (8.3) 16 (12.1) 0.406
>10 – 18 years 11 (10.0) 13 (11.0) 0.283
Median (IQR) Median (IQR) P value*
Viral load (x10 4) Overall 12.0 (2.4 – 38.6) 7.8 (2.3 - 35) 0.176
≤ 5 years 18.8 (2.9 – 75) 17.7 (2.5 – 52.5) 0.283
>5-10 years 4.4 (1.5 – 17.4) 6.1 (1.8 – 28.6) 0.658
>10 – 18 years 13.1 (2.4 – 37.0) 7.6 (2.0 – 25.5) 0.183
* P value based on Wilcoxon rank-sum test.
The baseline CD4 counts, and viral loads were.
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Majority of the children who failed first-line ART were
under five years of age (n = 91; 37.9%), male (52.5%), were
under the care of parents (n = 162; 67.5%). Their caretakers
attained primary education as the highest level (31.9%),
as shown in Table 1. When compared to the controls,
the children who failed first-line ART were more likely
to live within 10 km from the ART providing institution
(RR = 1.27(95% CI: 1.03-1.56), p = 0.02). Furthermore, the
children who never failed were more likely to be under
the care of grandmothers [(17.6% versus 10.4%), RR = 0.65
(95% CI: 0.46 -0.93), p = 0.01]. There was no statistical
significance between the baseline CD4cell counts of the
controls and cases (illustrated in Table 2).Table 3 Factors independently associated with treatment
failure among the children on ART in the cohort at
multivariate analysis
Effect OR (95% CI) P- value
CD4 counts at start of ART 0.99 (0.99-1.00) 0.027
Viral load at start of ART 0.99 (0.99-1.00) 0.402
NOK (Relationship)‡ Parents 0.9 (0.61 – 1.60) 0.965
Grandmother 0.8 (0.42 – 1.55) 0.517
HAART Regimen NVP 2.2 (1.40 – 3.60) 0.006*
Used sdNVP Yes 4.2 (1.80 – 9.40) 0.001*
Adherence Poor 10,0 (6.40 – 16.70) <0.001*
Distance from JCRC‡‡ ≤10 km 1.48 (0.88 – 2.49) 0.142
11 – 20 km 1.21 (0.72 – 2.03) 0.470
CI = Confidence interval, * Significant effect. ‡ Reference to other caretakers.Past hospitalization, opportunist Infections and WHO
clinical staging were not associated with treatment failure.
However, nevirapine as opposed to efavirenz as NNRTI
backbone (OR = 2.2., 95% CI: 1.40 – 3.60, p = 0.001), poor
adherence (OR = 10, 95% CI: 6.4 – 16.7), p < 0.0001) and
prior exposure to (sdNVP) (OR = 4,2, 95% CI: 1.8 – 9,4,
p = 0.002) were the significantly associated with first line
ART treatment failure (Table 3). It important to note that
the Viral load and CD4 at initiation of first line ART were
not associated with treatment failure.
Resistance associated mutation (RAM) in the children
with treatment failure
Of the 240 children who failed first line therapy 109 had
genotypic resistance profiles prior to switching to second
line therapy. The commonest NNRTI RAMs was K103N
(n = 59; 54%). Other common NNRTI RAMs were Y181C
(n = 30; 27%), G190A (n = 26; 24%) and K101E (n = 11;
10%). The most common NRTI RAMs was the M184V
(n = 89; 81%). Other common NRTI RAMs were the
K70R (n = 22; 20%), T215Y (n = 36; 24%), M41L (n = 23;
21%), D67N (n = 15; 14%), K219Q/E (n = 14; 13%) and the
L210W making 9% of the TAMs.
It’s worth noting that some patients had developed more
than one resistance mutation at a time.
Discussion
In this study, we have shown that the cumulative incidence
of first line ART failure was 34%, with a median time to
first line ART failure of 26.4 months of follow up. Varying
rates of virological failure have been reported in other
Figure 1 Study profile of the study participants.
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this study is comparable to other studies in low income
countries with a high prevalence of HIV. A similar study
done in rural South Africa on 101 HIV infected children
reported a slightly higher virological failure rates of 38%
compared to ours, with a median duration of NNRTI-
based regimen of 31 months of treatment [15]. A compar-
able rate of 33% was reported among the Thai HIV infected
children within 96 weeks of follow up [23].
In our study, patients were more likely to fail on a
nevirapine NNRTI regimen compared to an efavirenz
based NNRTI backbone regimen. This finding has beendocumented in similar studies. In the FIRST STUDY [24]
by Berg-Wolf et al., the incidence of virological failure in
an efavirenz based arm was 41.2 compared to 42.8 in
the nevirapine arm per 100 person years after a follow
up median time of 5 years. Implying that a NVP based
regimen arm was associated with earlier virological failure
compared to efavirenz, like our study finding.
Our study showed that treatment failure rate was more
in males than the female though the difference was not sta-
tistically significant. A cohort of HIV infected children and
adults performed in a similar setting (Mulago, Kampala,
Uganda) reported that males were more likely to fail on
Table 4 Baseline clinical and demographic characteristics
of the study participants at the time of ART initiation
Characteristic Frequency %
Age <=5 years 265 37.80
>5-10 years 200 28.53
>10 – 18 years 236 33.67
Gender Female 330 47.08
Male 371 52.92
Next of kin Parents 464 66.19
Grandmother 106 15.12
Other 131 18.69
Caretaker education level None 164 23.77
Primary 251 36.38
Secondary 160 23.19
Tertiary (not university) 69 10.00
University 46 6.67
Past hospitalization Yes 303 43.41
No 395 56.59
Episodes of 0 days 5 1.69
Hospitalization 1-2 days 188 63.51
≥ 3 days 103 34.80
Opportunistic infections TB 141 20.11







Bacterial meningitis 7 1.00
HAART regimen EFV 391 59.24
NVP 269 40.76
UsedPMTCT services Yes 31 6.22
No 617 88.78
Adherence Poor (<95%) 172 24.54
Good (>95%) 529 75.46
I 102 14.55
WHO stage II 304 43.37
III 248 35.38
IV 47 6.70
TB: tuberculosis, CCM: cryptococcal meningitis; KS, Kaposi’sarcoma; LIP,
Lymphoid interstitial pnemonitis; PCP, pnenocystic carinii pneumonia; EFV,
efaverenz; NVP, niverapine.
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Figure 2 Kaplan Meier survival curve estimating the overall
time to failure.
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difference is not known. Interestingly, there were more
male children in our study compared to the Mulago study.
Sex differences in response to ART could be biological orrelated to provision of care by parents. This is an area that
requires further inquiry.
The factors that were independently associated with
treatment failure were poor adherence to ART, use of sin-
gle dose niverapine (sdNVP) in PMTCT and NVP based
NNRTIs.
The critical role of adherence in the treatment of HIV
has been demonstrated in many clinical trials and clinical
care settings [25]. Antiretroviral therapy (ART) adherence
is a strong predictor of biological (virological and im-
munological) and eventual clinical outcome [26-28]. This
study findings are consistent with previous studies [25]
and further confirms that adherence to ART is critical in
the clinical, and biological outcome of ART. Our study
further demonstrated that the use of single dose niverapine
(sdNVP) as a measure of PMTC of HIV was strongly
associated with ART first line treatment failure. This is
attributed to the fact that NVP resistance occurs after
the use of sdNVP as reported in many studies from all over
Sub-Saharan Africa, Uganda inclusive [15,29-31]. A meta
analysis to analyze the prevalence of nevirapine resistance
after sdNVP was 35.7% in women and 52.6% in children
[13]. The landmark HIVNET 012 trial in Uganda revealed
a resistance of 46% in children and 25% in women [32].
These findings are also similar to what was reported
among Ugandan children who had been exposed to sdNVP
that were less likely to achieve virological suppression if
initiated on a non nucleoside reverse transcriptase inhibitor
(NNRTI) [33] regimen. For a long time in Uganda, NVP
was used for PMTCT of HIV and has also been part of the
backbone of the NNRTI regimen. It is worth noting that
the study participants had been initiated on ART between
2004 to 2009 in which usage of protease Inhibitors (PI) as
Table 5 Factors associated with time to failure among the children who failed ART
Effect Coefficient (s.e) Hazard ratio (95% CI) P- value
Age† <=5 years 0.11 (0.19) 1.18 (0.82 – 1.69) 0.551
>5-10 years −0.05 (0.18) 0.96 (0.67 – 1.38) 0.767
NOK (Relationship) ‡ Parents 0.13 (0.27) 0.42 (0.24 – 0.74) 0.453
Grandmother −0.52 (0.59) 0.86 (0.58 – 1.28) 0.053°
HAART regimen†† EFV −0.11 (0.16) 0.69 (0.44 – 1.08) 0.493
Used PMTCT services Yes 0.03 (0.23) 0.86 (0.54 – 1.39) 0.888
Adherence Poor −0.38 (0.14) 1.06 (0.50 – 1.10) 0.008*
Distance from JCRC ≤10 km 0.37 (0.21) 1.45 (0.97 – 2.18) 0.073
11 – 20 km 0.36 (0.21) 1.43 (0.95 – 2.16) 0.091
† Reference to age >10 -18 yrs, ‡ Reference to other caretakers.
°Borderline significance, †† Reference to NVP, * Significant effect.
NOK next of kin, PMTCT prevention of mother to child transmission.
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to sdNVP had not been rolled out in Uganda after the
recommendation from the World health Organization in
2010. It’s possible that some children could have remained
on a failing regimen after exposure to sdNVP thus treat-
ment failure.
In this study children who were initiated on a NVP
based first line ART were twice as likely to fail compared
to those treated with EFV containing one. A prospective
longitudinal study in Thailand reported that children on
a NVP backbone NNRTI were 3.7 times more likely to
develop virological failure compared to efavirenz [21].
These results are also consistent with earlier findings
in Kampala, Uganda [22]. The finding in this study could
further be explained by the fact that efavirenz is more effi-
cacious than nevirapine [34,35] as reported in some studies.
Secondly NVP compared to EFV is commonly associated
with adverse side effects and increased morbidity and
mortality [36]. In the event that adverse events occur
the drugs are stopped and this could contribute to poor
adherence with eventual drug resistance and treatment
failure.
A grandmother being the primary caretaker was less
associated with treatment failure compared to other
caretakers at univariate analysis. However this factor did
not reach statistical significance at multivariate analysis
possibly due to the small numbers of children whose
primary caretaker were grandmothers. A recent Ugandan
study [37] reported that children in the rural settings of
Uganda had better adherence compared to their urban
counterparts(91.3% vs 88.2%). Majority of grandparents in
Uganda reside in rural settings and often offer more time
and parental care to their grand children hence good
adherence. This could explain why children whose primary
caretaker was a grandmother never failed in big proportions
as compared to others with different care takers.
Resistance profiles that were performed prior to switch-
ing to second line, revealed the M184V and the K103Nbeing the commonly observed NRTI and NNRTI RAMs,
respectively. TAMs occurred in 20% of the resistance
profiles. This pattern of RAMs among children with
virological failure on reverse transcriptase based therapy is
consistent with what has been reported from studies in
sub-Saharan Africa [22,38,39], Thailand. In the Thai chil-
dren [21], Y181C occurred in 58% and K103N in 34% of
NNRTIs RAMs. In the same study M184V/I occurred in
84%, K65R in 11%, and Q151M in 5% with TAMs occur-
ring in 18% of the NRTIs resistance mutations. The current
study reports more of the K103N as opposed to the Y181C
in the NNRTIs while the proportion of M184V was consist-
ent with the previous study. This finding was expected as
most of the children at JCRC (current study) were on an
efavirenz containing regimen that induces commonly the
K103N as opposed to nevirapine that induces commonly
the Y181C [34] which occurred in the Thai study. The
NNRTIs and 3TC have a low genetic barrier to resistance.
So their RAMs are the first to appear. M184V has been
shown to emerge in high prevalence among children and
adults failing on a 3TC-containing regimen in developed
countries [40]. In Uganda, it’s been reported in children as
early as 1.5 months [38] of ART. Other cross sectional
studies have likewise reported a high prevalence of
M184Vamong African [41,42] with mutations conferring
resistance to NVP and EFV the NNRTIs occurring after
1–6 months of failure. This study showed occurrence of
all the major TAMs in 20%. This finding is comparable to
what Thai reports of 18% [21]. However this is in contrast
to earlier reports from Uganda [20,39] that reported nearly
no TAMs. Our finding could have resulted from the fact
that our study had a big sample size compared to the
above studies. Secondly a possibility of mother to child
transmission of the RAMs since baseline resistance testing
prior to ART initiation was never done cannot be ruled
out. However this study highlights the fact that the thy-
mine analogue mutations are present in our setting and
their presence will compromise second line ART options.
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http://www.aidsrestherapy.com/content/10/1/25Study strength and limitations
We studied a relatively large number of HIV infected
children on ART to examine the incidence of and median
time to first line ART failure compared to similar studies.
We however acknowledge some limitations in our study.
Being a retrospective nested case control, we could not
control for some of the possible confounders. Secondly
baseline resistance testing was not done, so the exact
impact of primary drug resistance prior to ART initiation
and the accumulation of RAMs is unknown.Conclusion and recommendations
In a low resource setting where nevirapine still forms a
backbone of first-line ART like Uganda, our findings
suggest that one in three children on first-line ART are
likely to develop virological treatment failure after the
first 24 months of therapy.
We recommend that, efavirenz as opposed to nevirapine
be used as first-line non-nucleoside backbone. Further-
more that adherence to ART should be emphasized at all
levels of care in paediatric ART service providers to pre-
vent the development of treatment failure.
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